[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540057":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":48,"responsibleParty":65,"collaborators":33,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":33,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":33,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":33,"overallStatus":51,"whyStopped":33,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Xiyuan Hospital of China Academy of Chinese Medical Sciences","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"photosensitizer group","EXPERIMENTAL","Subjects will receive a photodynamic therapy with chlorin-e6 after acne removal surgery.Each subject will receive three treatments, two weeks (±3 days) intervals.",[13,14],"Drug: N-chlorin e6 triglumine","Procedure: acne removal surgery",{"label":16,"type":17,"description":18,"interventionNames":19},"photosensitizer-placebo group","PLACEBO_COMPARATOR","Subjects will receive a red light exposure treatment with chlorin-e6 placebo after acne removal surgery.Each subject will receive three treatments, two weeks (±3 days) intervals.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","N-chlorin e6 triglumine","a photodynamic therapy with chlorin-e6",[9],[27],"a red light irradiation",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"PROCEDURE","acne removal surgery","acne removal surgery will be given before red light exposure",[9,16],null,[35],{"name":36,"affiliation":37,"role":38},"Huiyan Chi, doctor","Deputy director of dermatology","STUDY_DIRECTOR",[40,44],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},"CONTACT","13811626953","chihuiyan@163.com",{"name":45,"role":41,"phone":46,"phoneExt":33,"email":47},"Yisheng Zhang, doctor","15652386117","llleera@126.com",[49],{"facility":50,"status":51,"city":52,"state":33,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Xiyuan Hospital of China Academy of Chinese Medical Sciences Organization","RECRUITING","Beijing","100091","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63,64],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},{"name":45,"role":41,"phone":46,"phoneExt":33,"email":47},{"type":66,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100540057","phase-2-study-to-evaluate-the-efficacy-safety-and-tolerability-of-photodynamic-therapypdt-with-chlorin-e6-in-treating-moderate-to-severe-acne-100540057",false,"NCT06311890","Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne","Inclusion Criteria:\n\n1. Subject is male or non-pregnant female 18 years of age and younger than 50 years of age.\n2. Subject has moderate to severe facial acne vulgaris.\n3. Subject has provided written informed consent.\n\nExclusion Criteria:\n\n1. People who are taking photosensitive drugs;\n2. Allergic to any component of the photosensitizer;\n3. porphyrins or allergies to porphyrins, with a history of photosensitivity;\n4. Pregnant or lactating women and those planning to become pregnant within 3 months;\n5. Oral or topical antibiotics, retinoids, glucocorticoids, peroxybenzoyl and other drugs within the past 1 month;\n6. Have a history of exposure to sunlight in the past 1 month, have received photoelectric treatment in the past 3 months, or have received facial grinding treatment in the past six months;\n7. are using vasodilators (such as nitroglycerin, etc.), beta blockers (such as metoprolol, etc.), anticoagulants (such as warfarin, etc.) and other drugs that easily cause facial capillary dilatation;\n8. Patients with facial rosacea, atopic dermatitis, hormone-dependent dermatitis and other facial skin-related diseases;\n9. Abnormal blood and urine routine, liver and kidney function, diseases of important organs and hematopoietic system that researchers believe are not suitable for clinical trials;\n10. Patients participating in other clinical trials at the same time.","ALL","18 Years","50 Years",{"count":77,"type":78},46,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability.",[84,85],"Acne","Photodynamic Therapy","2024-03-13",{"date":88,"type":89},"2024-03-15","ACTUAL",{"date":91,"type":89},"2024-02-01",{"date":93,"type":78},"2026-09-30",{"name":5,"class":6},1]